Literature DB >> 1906392

Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye.

S W Cousins1, W B Trattler, J W Streilein.   

Abstract

Immunologic privilege of the anterior chamber has been associated with the capacity to induce a unique form of deviant systemic immunity after anterior chamber (AC) immunization. However, the capacity of privilege to suppress expression of immunity in the AC has not been examined. We studied the ability of the AC to sustain immunogenic inflammation after direct antigen challenge (delayed hypersensitivity-DH) in C57BL/6 mice primed to M tuberculosis (MT) antigens. Compared to subcutaneous and subconjunctival sites where primed mice demonstrated vigorous and significant DH, the anterior chambers of these mice failed to develop signs of inflammation unless toxic doses of antigen were injected. In an attempt to promote intraocular DH, the AC's of MT-primed mice were pre-treated with subinflammatory intracameral injections of IFN-gamma, a cytokine that antagonizes TGF-beta, recruits antigen presenting cells (APC) from the blood and activates resident APC precursors. It was observed that AC injection of IFN-gamma, followed 3 days later by AC challenge with 200 ng of MT, resulted in severe intraocular inflammation only in primed (but not naive) mice. We conclude that the normal mouse AC resists DH unless its immunosuppressive microenvironment is abolished, as in these experiments by IFN-gamma. We propose that impaired expression of cell-mediated immunity is an important component of immune privilege of the AC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906392     DOI: 10.3109/02713689108996334

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  13 in total

1.  Retinal laser burn disrupts immune privilege in the eye.

Authors:  Hong Qiao; Kenyatta Lucas; Joan Stein-Streilein
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

2.  Polarized secretion of IL-6 and IL-8 by human retinal pigment epithelial cells.

Authors:  G M Holtkamp; M Van Rossem; A F de Vos; B Willekens; R Peek; A Kijlstra
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

3.  Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis.

Authors:  W J O'Brien; J L Taylor; H Ankel; G Sitenga
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  Fuchs' heterochromic cyclitis: review of the literature on the pathogenetic mechanisms.

Authors:  E La Hey; P T de Jong; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1994-04       Impact factor: 4.638

Review 5.  Applications of the role of α-MSH in ocular immune privilege.

Authors:  Andrew W Taylor; Darren Lee
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

6.  Localized retinal neuropeptide regulation of macrophage and microglial cell functionality.

Authors:  Norikuni Kawanaka; Andrew W Taylor
Journal:  J Neuroimmunol       Date:  2010-10-20       Impact factor: 3.478

7.  Inflammatory Cytokine-Mediated Regulation of Thrombospondin-1 and CD36 in Conjunctival Cells.

Authors:  Laura Soriano-Romaní; Laura Contreras-Ruiz; Laura García-Posadas; Antonio López-García; Sharmila Masli; Yolanda Diebold
Journal:  J Ocul Pharmacol Ther       Date:  2015-07-08       Impact factor: 2.671

8.  Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis.

Authors:  Yan Ke; Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-16       Impact factor: 4.799

9.  Ocular immune privilege.

Authors:  A W Taylor
Journal:  Eye (Lond)       Date:  2009-01-09       Impact factor: 3.775

10.  Polymorphisms of IL23R and Fuchs' syndrome in a Chinese Han population.

Authors:  Hongyan Zhou; Zhengxuan Jiang; Peizeng Yang; Shengping Hou; Fuzhen Li; Qinmeng Shu; Yuanyuan Chen; Feilan Chen
Journal:  Mol Vis       Date:  2010-12-05       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.